A role of aurora A tyrosine kinase inhibitor, Alisertib, in the resistance of cancer cells to Daunorubicin

被引：0
|
作者：
Yati, S. [1 ]
Novotna, E. [1 ]
Wsol, V. [1 ]
机构：
[1] Charles Univ Prague, Dept Biochem Sci, Hradec Kralove, Czech Republic
来源：
TOXICOLOGY LETTERS | 2024年 / 399卷
关键词：
D O I：
10.1016/j.toxlet.2024.07.905
中图分类号：
R99 [毒物学（毒理学）];
学科分类号：
100405 ;
摘要：
LP-42
引用
收藏
页码：S380 / S381
页数：2
相关论文
共 50 条
  • [1] Molecular mechanism underlying acquired resistance to Aurora A kinase inhibitor, Alisertib, in melanoma
    Vilgelm, Anna E.
    Liu, Yan
    Levy, Shawn
    Richmond, Ann
    CANCER RESEARCH, 2012, 72
  • [2] THE AURORA KINASE A INHIBITOR ALISERTIB IS SYNERGISTIC WITH IRINOTECAN AND CARBOPLATIN AGAINST GLIOBLASTOMA CELLS
    Burton, Eric
    Zumbar, Cory
    King, Paul
    Sak, Muge
    Usubalieva, Aisulu
    Li, Xiaohui
    Mifsud, Caroline
    McElroy, Joseph
    Lehman, Norman
    NEURO-ONCOLOGY, 2018, 20 : 101 - 101
  • [3] An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor
    Durlacher, Cameron T.
    Li, Zhi-Ling
    Chen, Xiao-Wu
    He, Zhi-Xu
    Zhou, Shu-Feng
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2016, 43 (06) : 585 - 601
  • [4] Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer
    Goff, Laura W.
    Azad, Nilofer S.
    Stein, Stacey
    Whisenant, Jennifer G.
    Koyama, Tatsuki
    Vaishampayan, Ulka
    Hochster, Howard
    Connolly, Roisin
    Weise, Amy
    LoRusso, Patricia M.
    Salaria, Safia N.
    El-Rifai, Wael
    Berlin, Jordan D.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 315 - 322
  • [5] Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer
    Laura W. Goff
    Nilofer S. Azad
    Stacey Stein
    Jennifer G. Whisenant
    Tatsuki Koyama
    Ulka Vaishampayan
    Howard Hochster
    Roisin Connolly
    Amy Weise
    Patricia M. LoRusso
    Safia N. Salaria
    Wael El-Rifai
    Jordan D. Berlin
    Investigational New Drugs, 2019, 37 : 315 - 322
  • [6] Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
    Wang, Lihong
    Arras, Janet
    Katsha, Ahmed
    Hamdan, Saif
    Belkhiri, Abbes
    Ecsedy, Jeffrey
    El-Rifai, Wael
    MOLECULAR ONCOLOGY, 2017, 11 (08) : 981 - 995
  • [7] Scientific rationale supporting the clinical development strategy for the investigational Aurora A kinase inhibitor alisertib in cancer
    Niu, Huifeng
    Manfredi, Mark
    Ecsedy, Jeffrey A.
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [8] Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
    Pitts, Todd M.
    Bradshaw-Pierce, Erica L.
    Bagby, Stacey M.
    Hyatt, Stephanie L.
    Selby, Heather M.
    Spreafico, Anna
    Tentler, John J.
    McPhillips, Kelly
    Klauck, Peter J.
    Capasso, Anna
    Diamond, Jennifer R.
    Davis, S. Lindsey
    Tan, Aik Choon
    Arcaroli, John J.
    Purkey, Alicia
    Messersmith, Wells A.
    Ecsedy, Jeffery A.
    Eckhardt, S. Gail
    ONCOTARGET, 2016, 7 (31) : 50290 - 50301
  • [9] A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)
    Beltran, H.
    Danila, D.
    Montgomery, B.
    Szmulewitz, R.
    Vaishampayan, U.
    Armstrong, A.
    Stein, M.
    Hoimes, C.
    Pinski, J.
    Scher, H.
    Puca, L.
    Bareja, R.
    Wong, W.
    Rubin, M.
    Mosquera, J. M.
    Sboner, A.
    Oromendia, C.
    Nanus, D.
    Ballman, K.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] A phase 2 study of the Aurora A kinase (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pretreated urothelial cancer (UC)
    Necchi, Andrea
    Raggi, Daniele
    Lo Vullo, Salvatore
    Mariani, Luigi
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Nicolai, Nicola
    Perrone, Federica
    Pelosi, Giuseppe
    Salvioni, Roberto
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345